Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-α induced hepatocyte apoptosis

BMC Complementary and Alternative Medicine

Cheng-hai Liu¹  Zu-long Liu²  Li Shen²  Tao Zhou²  Xiu-chuan Yan²  Yan-yan Tao² 

[1] E-Institute of TCM Internal Medicine, Shanghai Municipal Education Commission, Shanghai 201203, China;Institute of Liver Diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai 201203, China

关键词: Liver fibrosis;    Apoptosis;    Hepatic stellate cell;    Hepatocyte;    Fuzheng Huayu recipe;   

Others  :  1085395
DOI  :  10.1186/1472-6882-14-449

 received in 2014-04-08, accepted in 2014-09-19,  发布年份 2014

【 摘 要 】

Background

What was the relationship of Fuzheng Huayu recipe (FZHY) inhibiting hepatocyte apoptosis and HSC activation at different stage of liver fibrosis? In order to answer this question, the study was carried out to dynamically observe FZHY’s effect on hepatocyte apoptosis and HSC activation and further explored underling mechanism of FZHY against hepatocyte apoptosis.

Methods

Mice were randomly divided into four groups: normal, model, FZHY, and N-acetylcystein (NAC) groups. Acute hepatic injury and liver fibrosis in mice were induced by CCl₄. Three days before the first CCl₄ injection, treatment with FZHY powder or NAC respectively was started. In vitro, primary hepatocytes were pretreated with FZHY medicated serum or Z-VAD-FMK and then incubated with ActD and TNF-α. Primary HSCs were treated with DNA from apoptotic hepatocytes incubated by Act D/TNF-α or FZHY medicated. Liver sections were analyzed for HE staining and immunohistochemical evaluation of apoptosis. Serum ALT and AST, Alb content and TNF-α expression in liver tissue were detected. Hyp content was assayed and collagen deposition was visualized. Expressions of α-SMA and type I collagen were analyzed by immunofluorescence and immunoblotting. Flow cytometry, immunofluorescence, and DNA ladder for hepatocyte apoptosis and immunoblotting for TNF-R1, Bcl-2 and Bax were also analyzed.

Results

Mice showed characteristic features of massive hepatocytes apoptosis in early stage of liver injury and developed severe hepatic fibrosis in later phase. FZHY treatment significantly alleviated acute liver injury and hepatocyte apoptosis, and inhibited liver fibrosis by decreasing α-SMA expression and hepatic Hyp content. In vitro, primary hepatocytes were induced by TNF-α and Act D. The anti-apoptotic effect of FZHY was generated by reducing TNFR1 expression and balancing the expressions of Bcl-2 and Bax. Meanwhile, the nuclear DNA from apoptotic hepatocytes stimulated HSC activation in a dose dependent manner, and the DNA from apoptotic hepatocytes treated with FZHY or Z-VAD-FMK reduced HSC activation and type I collagen expression.

Conclusion

These findings suggested that FZHY suppressed hepatocyte apoptosis through regulating mediators in death receptor and mitochondrial pathways, and the effect of FZHY on hepatocyte apoptosis might play an important role in inhibiting liver fibrosis.

【 授权许可】

   
2014 Tao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134(6):1655-1669.
• [2]Friedman SL: Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004, 1(2):98-105.
• [3]Jiang JX, Mikami K, Venugopal S, Li Y, Torok NJ: Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 2009, 51(1):139-148.
• [4]Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, Mehal WZ: Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007, 46(5):1509-1518.
• [5]Friedman SL: Evolving challeges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010, 7(8):425-436.
• [6]Fallowfield JA: Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011, 300(5):G709-G715.
• [7]Du B, You S: Present situation in preventing and treating liver fibrosis with TCM drugs. J Tradit Chin Med 2001, 21(2):147-152.
• [8]Zhang J, Xu L: [Advances of mechanism research on treatment of experimental liver fibrosis with traditional Chinese medicine]. Zhong Xi Yi Jie He Xue Bao 2003, 1(2):142-145.
• [9]Zhang B, Wang LT: [Progress in experimental study on inhibitory effect of traditional Chinese medicine on liver fibrosis]. Zhong Xi Yi Jie He Xue Bao 2006, 4(2):206-210.
• [10]Yang T, Shen DP, Wang QL, Tao YY, Liu CH: Investigation of the absorbed and metabolized components of Danshen from Fuzheng Huayu recipe and study on the anti-hepatic fibrosis effects of these components. J Ethnopharmacol 2013, 148(2):691-700.
• [11]Cheung KF, Ye DW, Yang ZF, Lu L, Liu CH, Wang XL, Poon RT, Tong Y, Liu P, Chen YC, Lau GK: Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol 2009, 124(1):142-150.
• [12]Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, Hu DC, Yin YK, Zhou XQ, Wan MB, Cai X, Zhang ZQ, Ye J, Tang BZ, He J: [Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B]. Zhong Xi Yi Jie He Xue Bao 2003, 1(2):89-98.
• [13]Liu P, Liu C, Xu LM, Hu YY, Xue HM, Liu CH, Zhang ZQ: Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B. World J Gastroenterol 1998, 4(4):348-353.
• [14]Liu P, Liu C, Hu YY: [Effect of fuzheng huayu recipe in treating posthepatitic cirrhosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1996, 16(8):459-462.
• [15]Liu C, Hu Y, Xu L, Liu P: Effect of Fuzheng Huayu formula and its actions against liver fibrosis. Chin Med 2009, 4:12-22. BioMed Central Full Text
• [16]Liu C, Wang X, Liu P: [Serapharmacological effect of fuzheng huayu 319 Decoction on expression of type I collagen and transforming growth factor beta 1 in hepatic stellate cells]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999, 19(7):412-414.
• [17]Zhou T, Yan X, Chen Q, Tao Y, Liu C: [Effect of Fuzheng huayu decoction on hepatocytic apoptosis and necrosis on acute liver injury due to LPS in mice]. Drug Evaluation 2008, 5(5):204-208.
• [18]Brunt EM: Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000, 31(1):241-246.
• [19]Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, Friedman SL: Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004, 127(3):870-882.
• [20]Xie H, Tao Y, Lv J, Pinsaa L: Proteomic analysis of the effect of fuzheng huayu recipe on fibrotic liver in rats. Evid Based Complement Alternat Med 2013, 972863:972863.
• [21]Jamall IS, Finelli VN, Que Hee SS: A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981, 112(1):70-75.
• [22]Yan X, Zhou T, Tao Y, Wang Q, Liu P, Liu C: Salvianolic acid B attenuates hepatocyte apoptosis by regulating mediators in death receptor and mitochondrial pathways. Exp Biol Med 2010, 235(5):623-632.
• [23]Kitamura T, Itoh M, Noda T, Matsuura M, Wakabayashi K: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer 2004, 109(4):576-580.
• [24]Oberhammer F, Bursch W, Tiefenbacher R, Froschl G, Pavelka M, Purchio T, Schulte-Hermann R: Apoptosis is induced by transforming growth factor-beta 1 within 5 hours in regressing liver without significant fragmentation of the DNA. Hepatology 1993, 18(5):1238-1246.
• [25]Hatano E: Tumor necrosis factor signaling in hepatocyte apoptosis. J Gastroenterol Hepatol 2007, 22(Suppl 1):S43-S44.
• [26]Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ: Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000, 106(9):1127-1137.
• [27]Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schroder K, Brandes RP, Devaraj S, Torok NJ: Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 2012, 53(2):289-296.
• [28]Canbay A, Friedman S, Gores GJ: Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39(2):273-278.
• [29]Kim TH, Venugopal SK, Zhu M, Wang SS, Lau D, Lam KS, Clemens DL, Zern MA: A novel small molecule, LAS-0811, inhibits alcohol-induced apoptosis in VL-17A cells. Biochem Biophys Res Commun 2009, 379(4):876-881.
• [30]Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ: The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004, 308(3):1191-1196.
• [31]Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC: Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-te trafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther 2004, 309(2):634-640.
• [32]Eghbali-Fatourechi G, Sieck GC, Prakash YS, Maercklein P, Gores GJ, Fitzpatrick LA: Type I procollagen production and cell proliferation is mediated by transforming growth factor-beta in a model of hepatic fibrosis. Endocrinology 1996, 137(5):1894-1903.
• [33]Galicia-Moreno M, Rodriguez-Rivera A, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG, Muriel P: N-acetylcysteine prevents carbon tetrachloride-induced liver cirrhosis: role of liver transforming growth factor-beta and oxidative stress. Eur J Gastroenterol Hepatol 2009, 21(8):908-914.
• [34]Saini U, Gumina RJ, Wolfe B, Kuppusamy ML, Kuppusamy P, Boudoulas KD: Preconditioning mesenchymal stem cells with caspase inhibition and hyperoxia prior to hypoxia exposure increases cell proliferation. J Cell Biochem 2013, 114:2612-2623.
• [35]Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W: Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett 1997, 410(1):96-106.
• [36]Malhi H, Gores GJ, Lemasters JJ: Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006, 43(2 Suppl 1):S31-S44.
• [37]Cory S, Huang DC, Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22(53):8590-8607.
• [38]Takehara T, Tatsumi T, Suzuki T, Rucker EB 3rd, Hennighausen L, Jinushi M, Miyagi T, Kanazawa Y, Hayashi N: Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004, 127(4):1189-1197.